In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene buys stake in Mesoblast

This article was originally published in Scrip

Executive Summary

Celgene has agreed to buy a minority stake in Australian regenerative therapy firm Mesoblast, shelling out Aus$58.5m (US$45m) for 15.3 million shares, or around 4.8% of outstanding stock. The deal values Mesoblast's stock at Aus$3.82 per share, a 19% premium over its closing price of Aus$3.21 on 10 April, the last trading day before the transaction was announced. The firm's share price closed up 24% at Aus$3.99 on 13 April.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts